SLC5A2 and hydrops fetalis: In addition, the different SGLT-2 inhibitors, namely, dapagliflozin or empagliflozin, are not the covariates included in the final model, showing that there is no significant difference in the pharmacodynamics influencing the quality of life in HF patients between the SGLT-2 inhibitors: 10 mg/day dapagliflozin and 10 mg/day empagliflozin from the studies so far included in the analysis.